At the 2026 American Society of Clinical Oncology Annual Meeting, researchers from Miami's Sylvester Comprehensive Cancer Center revealed a breakthrough that could transform how doctors predict which solitary fibrous tumors will turn deadly. By studying the precise location where genetic material misfires inside cancer cells, scientists have identified a clear pattern: tumors with distal genetic variants were four times more likely to spread, while patients with proximal variants saw no metastasis at all.
Solitary fibrous tumors are rare sarcomas that develop in connective tissues—fat, muscle, blood vessels and fibrous tissue—and can appear almost anywhere in the body, though they most commonly strike the chest cavity. Until now, doctors have relied on a clinical scoring system called the Demicco score that weighs patient age, tumor size and microscopic appearance to guess at aggressiveness. But that approach leaves crucial information on the table: the tumor's actual genetic signature.
All solitary fibrous tumors share a specific genetic flaw called a NAB2-STAT6 fusion, which occurs when two neighboring genes on chromosome 12 snap apart and reconnect in the wrong way. The question that drove the Sylvester research team, led by pathology clinical professor Andrew Rosenberg and sarcoma medical oncologist Gina D'Amato, was whether the exact location of that genetic break could reveal how dangerous a tumor truly was.
The study, conducted as part of The Horowitz Solitary Fibrous Tumor Initiative—founded with patient advocate Joel Horowitz's philanthropic support—analyzed 48 patients treated at Sylvester. Researchers reviewed clinical outcomes and molecular profiles to see if the NAB2-STAT6 fusion breakpoint predicted disease behavior. They found a striking difference: tumors categorized as having distal variants (breakpoints farther downstream in the genetic sequence) were far more aggressive than those with proximal variants (breakpoints closer to the beginning). Among patients with distal variants, 25 percent developed spreading cancer. Among those with proximal variants, none did.
"This was one of the most striking findings," said Keerthana Sureshkumar, a medical student and first author of the study. "Despite the relatively small sample size, we saw very strong signals that these molecular differences may carry important information about the patients' prognosis."
The differences went beyond metastasis rates. Distal variants tended to occur outside the chest cavity, appeared in larger tumors, and were more likely to recur after treatment. Proximal variants clustered in the chest, in smaller tumors with less aggressive behavior.
What makes this discovery significant is not just the finding itself, but what it enables: the shift from guesswork to precision medicine. "Instead of patients cycling through many different therapies, our goal is to better understand which tumors are more aggressive and which treatments may work best based on the biology of the disease," D'Amato said. For patients with distal variants, doctors could now justify more aggressive upfront treatment. For those with proximal variants, a more measured approach might spare unnecessary toxicity.
Rare tumor research demands specialized infrastructure and collaborative teams—tissue banks, molecular profiling labs, and patient registries that Sylvester has built over years. This study proves that investment pays dividends: genetic markers that were invisible just months ago now offer hope of better outcomes for a disease that has long left patients and doctors with too few answers.